Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGlaukos Corp

Glaukos Corp

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
240.965 USD 7.92 ( 3.40%)
Last update at 2026-11-04T15:00:00Z
VOLUME
129715
Market Cap
10126.36M

Momentum Score

…

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
235.95
Low
242.95
High
52 Week Price Range
73.16
Low
191.62
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Glaukos Corporation develops and sells ophthalmic devices including micro‑invasive glaucoma surgery implants (iStent family), intracameral sustained‑release drug implants, and corneal cross‑linking systems from its Avedro unit. Long‑term growth may be driven by aging populations and higher glaucoma incidence, wider MIGS adoption, geographic expansion and progress in drug‑delivery programs, which could support recurring procedure and device revenue.

The company faces material risks from regulatory and reimbursement uncertainty, reliance on surgeon adoption and procedural volumes, competitive pressure from larger ophthalmic players, and execution risk in clinical and commercial expansion.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
233.04
Dividend Yield
-
Revenue TTM
612.84M
Revenue Per Share
10.58
Gross Profit TTM
484.88M
Debt / Equity
0.21
ROE
-25.98%
Net Debt
48.83M
ROCE
-23.78%
Diluted EPS TTM
-3.28

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -193.04M -145.60M -133.73M -98.43M -49.27M
Net income -187.69M -146.37M -134.66M -99.19M -49.59M
Selling general administrative 331.75M 259.25M 222.57M 192.93M 179.26M
Selling and marketing expenses - 3.60M 1.50M - -
Gross profit 282.76M 289.45M 239.14M 213.88M 227.38M
Reconciled depreciation 42.34M 39.92M 37.98M 35.95M 34.42M
Ebit -188.41M -135.56M -120.09M -102.31M -62.87M
Ebitda -150.31M -95.64M -82.12M -104.71M -65.89M
Depreciation and amortization 38.09M 39.92M 37.98M -2.40M -3.02M
Non operating income net other - - - 2.38M 1.29M
Operating income -199.60M -122.37M -128.70M -102.31M -62.87M
Other operating expenses 707.04M 505.85M 443.41M 385.18M 356.88M
Interest expense 4.63M 10.04M 13.63M 13.72M 13.37M
Tax provision -5.35M 0.77M 0.93M 0.77M 0.33M
Interest income 10.71M 11.11M 9.16M 2.38M 1.29M
Net interest income 6.08M 1.06M -4.47M -11.35M -12.08M
Non recurring - - - -20.00M -20.00M
Income tax expense -5.35M 0.77M 0.93M 0.77M 0.33M
Total revenue 507.44M 383.48M 314.71M 282.86M 294.01M
Total operating expenses 482.36M 411.82M 367.84M 316.20M 290.26M
Cost of revenue 224.68M 94.03M 75.58M 68.98M 66.63M
Total other income expense net 6.56M -23.23M -5.03M 3.88M 13.61M
Net income from continuing ops -187.69M -146.37M -134.66M -99.19M -49.59M
Net income applicable to common shares - - - -99.19M -49.59M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 893.49M 974.76M 940.41M 1002.38M 1049.70M
Intangible assets 141.92M 263.44M 282.96M 307.87M 332.78M
Other current assets 24.05M 12.46M 18.19M 17.25M 15.63M
Total liab 237.33M 207.82M 478.65M 472.38M 462.55M
Total stockholder equity 656.15M 766.93M 461.77M 530.00M 587.15M
Other current liab 76.65M 59.62M 60.57M 57.96M 56.03M
Common stock 0.06M 0.06M 0.05M 0.05M 0.05M
Capital stock 0.06M 0.06M 0.05M 0.05M 0.05M
Retained earnings -933.13M -745.44M -599.07M -464.41M -365.21M
Other liab - - - 17.54M 16.81M
Good will 66.71M 66.13M 66.13M 66.13M 66.13M
Other assets - - - 17.69M 18.52M
Cash 90.81M 169.63M 93.47M 119.53M 100.71M
Total current liabilities 101.28M 75.12M 74.01M 72.36M 63.36M
Current deferred revenue - - -1.31M - -
Net debt 48.83M -63.75M 290.27M 262.95M 281.67M
Short term debt - 2.47M 2.23M - -
Short long term debt total 139.64M 105.87M 383.74M 382.48M 382.38M
Other stockholder equity 1585.92M 1509.70M 1059.62M 997.34M 952.30M
Property plant equipment - - - 94.40M 146.13M
Total current assets 474.98M 449.79M 395.46M 443.86M 486.13M
Net tangible assets - - - 530.00M 188.24M
Short term investments 187.95M 149.29M 201.96M 233.17M 313.34M
Net receivables 108.61M 60.74M 39.85M 36.07M 33.44M
Long term debt - - 282.77M 281.40M 280.03M
Inventory 63.56M 57.68M 41.99M 37.84M 23.01M
Accounts payable 24.62M 13.03M 13.44M 14.40M 7.33M
Accumulated other comprehensive income 3.30M 2.62M 1.17M -2.98M 0.01M
Common stock total equity - - - 0.05M 0.05M
Retained earnings total equity - - - -464.41M -365.21M
Treasury stock - - - - -0.13M
Non currrent assets other 21.86M 25.45M 21.32M 17.69M 18.52M
Non current assets total 418.50M 524.96M 544.95M 558.52M 563.57M
Capital lease obligations 103.88M 103.40M 100.97M 101.08M 102.35M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -35.35M 47.83M 43.67M 75.90M -8.37M
Change to liabilities - - - 7.21M 12.45M
Total cashflows from investing activities -77.61M 47.83M 14.10M 44.78M -58.23M
Net borrowings -1.12M -1.59M -0.71M -0.53M -0.66M
Total cash from financing activities 11.89M 91.54M 15.04M 6.25M 39.26M
Change to operating activities - - - -2.05M -2.87M
Net income -133.66M -146.37M -134.66M -99.19M -49.59M
Change in cash -111.26M 76.16M -26.06M 16.48M 3.96M
Begin period cash flow 174.36M 93.47M 119.53M 110.12M 106.16M
End period cash flow 63.10M 169.63M 93.47M 126.60M 110.12M
Total cash from operating activities -46.34M -61.32M -57.76M -33.08M 24.71M
Depreciation 38.09M 39.92M 37.98M 35.95M 34.42M
Other cashflows from investing activities -22.16M -3.15M -3.17M -0.86M -2.08M
Change to inventory 2.65M -18.79M -4.83M -15.47M -7.70M
Change to account receivables -53.02M -21.97M -3.84M -3.14M 1.70M
Sale purchase of stock - -6.56M -3.27M 9.21M 30.94M
Other cashflows from financing activities 11.89M -6.56M -3.27M 6.78M 39.92M
Change to netincome - - - 40.78M 34.93M
Capital expenditures 7.67M 6.30M 20.25M 30.27M 47.78M
Change receivables - - - -3.14M 1.70M
Cash flows other operating - - - 5.16M 5.73M
Exchange rate changes - - - - -1.77M
Cash and cash equivalents changes - - - 17.95M 3.96M
Change in working capital -31.55M -39.47M -10.13M -13.45M 3.58M
Stock based compensation 63.22M 50.21M 43.53M 38.56M 30.15M
Other non cash items 24.04M 34.62M 5.65M 5.11M 7.19M
Free cash flow -54.01M -67.62M -78.01M -63.35M -23.08M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GKOS
Glaukos Corp		 7.92
3.40%		 240.97 - 2000.00 16.52 14.84 16.22 -57.89
ABT
Abbott Laboratories		 3.15
2.88%		 112.55 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 4.05
4.10%		 102.93 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 18.89
6.08%		 329.44 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 48.37 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

One Glaukos Way, Aliso Viejo, CA, United States, 92656

949 367 9600

https://www.glaukos.com

1094

Name Title Year Born
Mr. Thomas William Burns Chairman & CEO 1961
Mr. Joseph E. Gilliam Pres & COO 1977
Mr. Chris M. Calcaterra Exec. VP of Global Commercial Operations 1960
Dr. Mory Gharib Ph.D. Co-Founder NA
Mr. Alex R. Thurman Sr. VP & CFO 1970
Mr. Christopher William Lewis VP of Investor Relations & Corp. Affairs NA
Ms. Diane W. Biagianti Sr. VP & Gen. Counsel 1960
Ms. Diana A. Scherer VP of Compliance & Deputy Gen. Counsel NA
Ms. Michele M. Allegretto Sr. VP of HR NA
Mr. David S. Haffner Sr. VP of New Technologies NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ORE
CAD 2.77
+8.86%
APM
CAD 4.95
+8.08%
NUAG
CAD 7.37
+8.06%
BZ
CAD 4.03
+8.04%
AYA
CAD 34.85
+7.96%
HUT
CAD 73.56
-17.26%
PHX
CAD 11.13
-12.22%
IVN
CAD 7.93
-10.70%
EFN
CAD 20.09
-10.39%
OBE
CAD 13.62
-6.71%

Equity Sectors*

  • Basic Materials

    +3.73%

  • Communication Services

    +1.16%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.14%

  • Energy

    -1.87%

  • Financial Services

    +1.53%

  • Healthcare

    +1.50%

  • Industrials

    +0.03%

  • Real Estate

    +0.71%

  • Technology

    +0.40%

  • Utilities

    +0.35%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…